Objective: There is a paucity of observational data on antifibrotic therapy for idiopathic pulmonary fibrosis (IPF). We aimed to assess the course of disease of IPF patients with and without antifibrotic therapy under real-life conditions.Methods: We analysed data from a non-interventional, prospective cohort study of consecutively enrolled IPF patients from 20 interstitial lung disease expert centres in Germany. Data quality was ensured by automated plausibility checks, on-site monitoring, and source data verification. Propensity scores were applied to account for known differences in baseline characteristics between patients with and without antifibrotic therapy.Results: Among the 588 patients suitable for analysis, the mean +/- so age wa...
Background and objective Antifibrotic therapy with nintedanib or pirfenidone slows disease progress...
After introduction of the new international guidelines on idiopathic pulmonary fibrosis (IPF) in 201...
The aim was to evaluate the determinants of acute exacerbation (AE) and death in new cases of idiopa...
Background: Real-world data regarding outcomes of idiopathic pulmonary fibrosis (IPF) are scarce, ou...
Background: Real-world data regarding outcomes of idiopathic pulmonary fibrosis (IPF) are scarce, ou...
Background: There are substantial advances in diagnosis and treatment for idiopathic pulmonary fibro...
Background: There are substantial advances in diagnosis and treatment for idiopathic pulmonary fibro...
Background: There are substantial advances in diagnosis and treatment for idiopathic pulmonary fibro...
Background: There are substantial advances in diagnosis and treatment for idiopathic pulmonary fibro...
BACKGROUND: The PROOF registry is an observational study initiated in October 2013 with the aim to m...
[Abstract] Antifibrotic agents suppress the decline in forced vital capacity (FVC) and disease progr...
BACKGROUND: The PROOF registry is an observational study initiated in October 2013 with the aim to m...
Objective No studies have demonstrated the real-world efficacy of antifibrotics for progressive fibr...
The aim was to evaluate the determinants of acute exacerbation (AE) and death in new cases of idiopa...
The aim was to evaluate the determinants of acute exacerbation (AE) and death in new cases of idiopa...
Background and objective Antifibrotic therapy with nintedanib or pirfenidone slows disease progress...
After introduction of the new international guidelines on idiopathic pulmonary fibrosis (IPF) in 201...
The aim was to evaluate the determinants of acute exacerbation (AE) and death in new cases of idiopa...
Background: Real-world data regarding outcomes of idiopathic pulmonary fibrosis (IPF) are scarce, ou...
Background: Real-world data regarding outcomes of idiopathic pulmonary fibrosis (IPF) are scarce, ou...
Background: There are substantial advances in diagnosis and treatment for idiopathic pulmonary fibro...
Background: There are substantial advances in diagnosis and treatment for idiopathic pulmonary fibro...
Background: There are substantial advances in diagnosis and treatment for idiopathic pulmonary fibro...
Background: There are substantial advances in diagnosis and treatment for idiopathic pulmonary fibro...
BACKGROUND: The PROOF registry is an observational study initiated in October 2013 with the aim to m...
[Abstract] Antifibrotic agents suppress the decline in forced vital capacity (FVC) and disease progr...
BACKGROUND: The PROOF registry is an observational study initiated in October 2013 with the aim to m...
Objective No studies have demonstrated the real-world efficacy of antifibrotics for progressive fibr...
The aim was to evaluate the determinants of acute exacerbation (AE) and death in new cases of idiopa...
The aim was to evaluate the determinants of acute exacerbation (AE) and death in new cases of idiopa...
Background and objective Antifibrotic therapy with nintedanib or pirfenidone slows disease progress...
After introduction of the new international guidelines on idiopathic pulmonary fibrosis (IPF) in 201...
The aim was to evaluate the determinants of acute exacerbation (AE) and death in new cases of idiopa...